Unicycive Therapeutics Inc Stock News

LOS ALTOS, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in two investor events in December.

-   Remain on track to resubmit the New Drug Application (NDA) for oxylanthanum carbonate (OLC) by year end -   Presented new analysis of OLC data at American Society of Nephrology (ASN) which demonstrates that OLC significantly reduced pill burden in terms of both pill volume (7x) and pill count (2x) compared to currently available phosphate binders -   Ended Q3 with $42.7 million of cash with...

LOS ALTOS, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference on Monday...

Defendants allegedly overstated Unicycive's FDA readiness for its OLC NDA; later cGMP issues at a subcontractor led to FDA setbacks and stock drops.

Analysis of the data from the open-label pivotal trial of oxylanthanum carbonate (OLC) highlights that pill burden was significantly reduced in terms of both pill volume (7x) and pill count (2x) from pre-trial phosphate binder therapy Analysis of the data from the open-label pivotal trial of oxylanthanum carbonate (OLC) highlights that pill burden was significantly reduced in terms of both pill...

Cash runway into 2027, which is expected to support application resubmission, potential FDA approval, and launch of OLC Cash runway into 2027, which is expected to support application resubmission, potential FDA approval, and launch of OLC

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”). Unicycive is a clinical-stage biotechnology company. For more information, submit a form, email att...

NEW YORK , Oct. 14, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March 29, 2024 and June 27, 2025, both dates inclusive (the "Class Period"), of the important October 14, 2025 lead plaintiff deadline. So what: If you purchased Unicycive securities during the Class Period you m...